Quintet Private Bank Europe S.A. Raises Position in Pfizer Inc. $PFE

Quintet Private Bank Europe S.A. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 521,181 shares of the biopharmaceutical company’s stock after acquiring an additional 52,658 shares during the period. Quintet Private Bank Europe S.A.’s holdings in Pfizer were worth $13,280,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter worth $27,000. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the 2nd quarter worth about $29,000. Finally, Howard Hughes Medical Institute bought a new position in shares of Pfizer in the 2nd quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $25.56 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a market capitalization of $145.34 billion, a P/E ratio of 14.86 and a beta of 0.46. The firm has a 50 day moving average of $25.11 and a 200 day moving average of $24.81. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.